2023 Annual Report to Shareholders
Enjoyed this read?
Stay up to date with our latest research.
BACK TO NEWS
Related articles
Press Releases and Media
Executive Interview HotCopper with Dr Steven Gourlay: Xanamem: Alzheimer’s breakthrough set for 2025, 2026
HotCopper • March 5, 2025
Press Releases and Media
The furore over how to treat Alzheimer’s just got a lot more complicated
The Australian • February 27, 2025
Press Releases and Media
Actinogen announces peer-reviewed clinical pharmacology manuscript for Xanamem (emestedastat) published in Clinical Pharmacology in Drug Development journal
PR Newswire • February 12, 2025